Shilpa Medicare’s USFDA Inspection Analyzed
Shilpa Medicare recently finished a review by the US Food and Drug Administration (USFDA) at their factory in Jadcherla, India. The inspection, which lasted ten days and concluded on November 21, 2025, resulted in the issuance of a Form 483. This document lists some issues the factory needs to fix, but importantly, none of them were repeated problems.
Key Points
- USFDA inspection finished; Form 483 issued, no repeat issues.
- Factory produces sterile injectables, tablets, and capsules for global markets.
- US sales represent less than 1% of Shilpa Medicare’s total business.
- The facility meets standards of EMA, Health Canada, and more.
- No critical safety concerns were identified by the FDA.
- Shilpa Medicare’s global supply chain is confirmed and consistent.
This factory makes medicines that are shipped to countries like the United States, Europe, and other places around the world. The US only buys a small amount of these medicines – less than 1% of Shilpa Medicare’s business. The USFDA found some things the factory could improve, but they weren’t problems the factory had faced before.
The fact that the factory is approved by important organizations like the EMA in Europe and Health Canada shows that Shilpa Medicare follows very strict rules. This approval also means that medicines made at this factory can be sold in many different countries.
In short, Shilpa Medicare’s facility passed a key inspection, showcasing its commitment to quality and global market access.
“Consistent regulatory compliance strengthens Shilpa Medicare’s position as a trusted pharmaceutical supplier worldwide.”
